Trending at Lumira Ventures

Lumira Ventures is pleased that LQT Therapeutics has announced the closing of US$19M Series A financing to advance lead compound through Phase 1

Altamash Hashmi LQT Therapeutics, Main Page, Portfolio News

LQT Therapeutics, Inc. (LQTT) a pharmaceutical company pioneering the development of precision therapies for genetic heart diseases, today announced the successful completion of a US$19 million Series A financing.  LQTT is advancing a series of in-licensed compounds discovered and developed by Sanofi …